Abstract Library

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,

#3795 Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors – A pooled analysis of five clinical trials

Introduction: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in systemic oncological therapies is still unknown, and there is a lack of evidence, especially in uncommon neoplasms like neuroendocrine tumors (NET).

Conference:

Presenting Author:

Authors: Hernando Cubero J, Roca-Herrera M, Garcia Alvarez A, Raymond E, Kulke M,

Keywords: Sex, Toxicity, Tyrosine Kinase Inhibitor,